MedTrace Logo

MATCHED (MC-1 and ACE Therapeutic Combination for Hypertensive Diabetics)

NCT00157729 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 160

Last updated 2006-10-31

No results posted yet for this study

Summary

The purpose of this study is to determine whether MC-1 alone and in combination with an ACE inhibitor is effective in reducing blood pressure and metabolic dysfunctions associated with diabetes

Conditions

Interventions

DRUG

pyridoxal-5'-phosphate with and without ACE inhibitor

Sponsors & Collaborators

  • Medicure

    lead INDUSTRY

Principal Investigators

  • Yves Lacourciere, MD, FRCP · Centre Hospitalier de l'Universite Laval

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
85 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2004-08-31
Completion
2005-07-31

Countries

  • Canada

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00157729 on ClinicalTrials.gov